AlphAIAlphAI — Financial news for AI agents
SEC EDGAR$RAPP

Yeleswaram Krishnaswamy sold $2.5M of RAPP

Yeleswaram Krishnaswamy (Chief Development Officer) sold 50,160 shares of Rapport Therapeutics, Inc. (RAPP) at an average of $50.47 ($50.00–$51.06, $2.53M total) across 3 trades over 2026-08-24 to 2026-08-25 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Yeleswaram Krishnaswamy
Published Aug 26, 2026, 8:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 26, 2026, 8:47 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$RAPP
Bearish
medium confidence
Mentioned
$RAPP
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$RAPPBearishLow
01

Why it matters

The transaction provides fresh data on insider sentiment, useful for short‑term positioning.

02

Market read

Primary insider sale; modest trading relevance for RAPP.

03

What to watch

The 10b5‑1 plan pre‑arranged execution reduces the informational value of the sale.

Relevance 5/10Novelty 5/10Timing: filed after market close on 2026-08-26

Background

Form 4 filings disclose insider trades; a $2.5M sale by a senior officer is noteworthy for traders.

Company-level read

Ticker impact

$RAPPBearishMedium confidence
Context

Chief Development Officer sold 50,160 shares for $2.53M via a 10b5‑1 plan.

Expected impact

Possible modest downside of 2‑4% over the next few days.

Evidence & confidence

The sale size is material for a mid‑cap biotech and executed under a pre‑arranged plan, suggesting a neutral to slightly bearish signal.

Market effects

Sector

May prompt scrutiny of other biotech insider transactions.

Regional

Limited to US biotech investors.

Global

Low global impact.

Counterpoint

What could challenge this read

Insider may be diversifying; sale does not necessarily reflect company outlook.

Key entities

  • company
    Rapport Therapeutics, Inc.

    Biotech firm developing therapeutic candidates.

  • person
    Yeleswaram Krishnaswamy

    Chief Development Officer of Rapport Therapeutics.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

RAPP insider trading history →

Related articles

$RAPPMed

Rapport Therapeutics 3Q 2026: Revenue $0 Net loss $40.2M, EPS $(0.84) — 10-Q Summary

Rapport Therapeutics reported no revenue and a net loss of $40.2M in 3Q 2026, widening from a $26.9M loss in the prior-year quarter. Diluted EPS was $(0.84). The company began Phase 3 trials for RAP-219 in epilepsy and plans further trials in 2027. Collaboration revenue from Tenacia was $20M for the nine months. According to the company, they deferred one program and prioritized another.

tradingview.com
$RAPPHighAI 9/10

Rapport Therapeutics Reports Third Quarter 2026 Financials and Provides Business Update

Rapport Therapeutics, Inc. (RAPP) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Rapport Therapeutics Reports Third Quarter 2026 Financials and Provides Business Update Positive topline results from Phase 2 trial of RAP-219 in bipolar mania; initiation of two Phase 3 trials in bipolar mania expected in 2H 2027 Data from the Phase 2 FOS open-label

SEC EDGAR 8-K
$RAPPMedAI 9/10

Rapport Announces Closing of Public Offerings of Common Stock and Pre-Funded Warrants and Convertible Notes, Including Full Exercise of Underwriters’ Options to Purchase Additional Shares and Notes, as well as Concurrent Private Placement

Rapport Therapeutics (RAPP) closed public offerings of 9.76M shares of common stock at $21.00 per share, $172.5M in convertible notes, and a concurrent private placement of 1.43M shares. Total net proceeds are approximately $410.7M. Proceeds will fund clinical trials, R&D, and general corporate purposes. The notes have a 2.25% interest rate and mature in 2032.

finance.yahoo.com